US 2002/0165154 A1 · Lipoprotein-regulating medicaments

Abstract

Methods and pharmaceutical compositions useful for modulating lipoprotein levels in vivo. The invention stems from the discovery that activity of the Lipolysis Stimulated Receptor (LSR) can be inhibited or enhanced by exogenous agents, including polypeptides.

Claims1

Dependent claims

A method for treating obesity-related insulin resistance comprising the administration of an effective amount of a composition comprising an Apm1 polypeptide comprising SEQ ID NO:

11 to said individual.

Dependencies are inferred from the claim text.

Facts

Application

10/060,845Filed 29 Jan 2002

Priority

FR 97/100886 Aug 1997

Published

7 Nov 2002

Term ends

Not estimatedThe source records don’t support an estimate.

Classification18 codes

C07K 14/705
From animals; from humans: receptors; Cell surface antigens; Cell surface determinants
A61P 1/16
Drugs for disorders of the alimentary tract or the digestive system: for liver or gallbladder disorders, e.g. hepatoprotective agents,…
A61P 3/04
Drugs for disorders of the metabolism: anorexiants; Antiobesity agents
A61P 3/06
Drugs for disorders of the metabolism: antihyperlipidemics

Family

Application09/485,316Division · filed 4 Feb 2000

Application09/485,316A 371 of international · filed 4 Feb 2000

Application10/060,845Division · filed 29 Jan 2002

US 6,344,441 B1Related patent

US 6,946,444 B2Related patent

US 2002/0165154 A1This patent

From the US filing history. Foreign family members aren’t listed.

Lipoprotein-regulating medicaments

Life of this patent

Abstract

Claims1

Lipoprotein-regulating medicaments

Life of this patent

Abstract

Claims1